258 related articles for article (PubMed ID: 24105684)
61. Clinical development of HER3-targeting monoclonal antibodies: Perils and progress.
Jacob W; James I; Hasmann M; Weisser M
Cancer Treat Rev; 2018 Jul; 68():111-123. PubMed ID: 29944978
[TBL] [Abstract][Full Text] [Related]
62. Molecular targeted therapy for advanced gastric cancer.
Kim JG
Korean J Intern Med; 2013 Mar; 28(2):149-55. PubMed ID: 23525404
[TBL] [Abstract][Full Text] [Related]
63. The HER family as therapeutic targets in colorectal cancer.
Ye P; Wang Y; Li R; Chen W; Wan L; Cai P
Crit Rev Oncol Hematol; 2022 Jun; 174():103681. PubMed ID: 35462030
[TBL] [Abstract][Full Text] [Related]
64. Beyond HER2: Targeting the ErbB receptor family in breast cancer.
Drago JZ; Ferraro E; Abuhadra N; Modi S
Cancer Treat Rev; 2022 Sep; 109():102436. PubMed ID: 35870237
[TBL] [Abstract][Full Text] [Related]
65. Targeting the HER-kinase axis in cancer.
Gross ME; Shazer RL; Agus DB
Semin Oncol; 2004 Feb; 31(1 Suppl 3):9-20. PubMed ID: 15052539
[TBL] [Abstract][Full Text] [Related]
66. Targeted therapies in gastric cancer and future perspectives.
Yazici O; Sendur MA; Ozdemir N; Aksoy S
World J Gastroenterol; 2016 Jan; 22(2):471-89. PubMed ID: 26811601
[TBL] [Abstract][Full Text] [Related]
67. Insight into the medicinal chemistry of EGFR and HER-2 inhibitors.
Wang C; Gao H; Dong J; Wang F; Li P; Zhang J
Curr Med Chem; 2014; 21(11):1336-50. PubMed ID: 24251571
[TBL] [Abstract][Full Text] [Related]
68. Analysis of different HER-2 mutations in breast cancer progression and drug resistance.
Sun Z; Shi Y; Shen Y; Cao L; Zhang W; Guan X
J Cell Mol Med; 2015 Dec; 19(12):2691-701. PubMed ID: 26305917
[TBL] [Abstract][Full Text] [Related]
69. Breast Cancer,
Bose R; Ma CX
N Engl J Med; 2021 Sep; 385(13):1241-1243. PubMed ID: 34551235
[No Abstract] [Full Text] [Related]
70. HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives.
Fanotto V; Ongaro E; Rihawi K; Avallone A; Silvestris N; Fornaro L; Vasile E; Antonuzzo L; Leone F; Rosati G; Giuliani F; Bordonaro R; Scartozzi M; De Maglio G; Negri FV; Fasola G; Aprile G
Oncotarget; 2016 Oct; 7(42):69060-69074. PubMed ID: 27542243
[TBL] [Abstract][Full Text] [Related]
71. [Targeted therapies: the question of target detection and evaluation].
Penault-Llorca F
Bull Cancer; 2007; 94(7 Suppl):F245-8. PubMed ID: 17965004
[TBL] [Abstract][Full Text] [Related]
72. Predictive biomarkers along gastric cancer pathogenetic pathways.
Panarese I; De Vita F; Ronchi A; Romano M; Alfano R; Di Martino N; Zito Marino F; Ferraraccio F; Franco R
Expert Rev Anticancer Ther; 2017 May; 17(5):417-425. PubMed ID: 28277834
[TBL] [Abstract][Full Text] [Related]
73. Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer.
Roviello G; Ravelli A; Polom K; Petrioli R; Marano L; Marrelli D; Roviello F; Generali D
Cancer Lett; 2016 Mar; 372(2):187-91. PubMed ID: 26797419
[TBL] [Abstract][Full Text] [Related]
74. Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network.
Lebedeva G; Sorokin A; Faratian D; Mullen P; Goltsov A; Langdon SP; Harrison DJ; Goryanin I
Eur J Pharm Sci; 2012 Jul; 46(4):244-58. PubMed ID: 22085636
[TBL] [Abstract][Full Text] [Related]
75. Targeted Agents in Esophagogastric Cancer Beyond Human Epidermal Growth Factor Receptor-2.
Mehlhaff E; Miller D; Ebben JD; Dobrzhanskyi O; Uboha NV
Hematol Oncol Clin North Am; 2024 Jun; 38(3):659-675. PubMed ID: 38485551
[TBL] [Abstract][Full Text] [Related]
76. Targeting HER receptors in cancer.
Ocaña A; Pandiella A
Curr Pharm Des; 2013; 19(5):808-17. PubMed ID: 22973952
[TBL] [Abstract][Full Text] [Related]
77. Neratinib (Nerlynx) for HER2-positive breast cancer.
Med Lett Drugs Ther; 2018 Jan; 60(1539):23. PubMed ID: 29364199
[No Abstract] [Full Text] [Related]
78. Molecular targeting to treat gastric cancer.
Aoyagi K; Kouhuji K; Kizaki J; Isobe T; Hashimoto K; Shirouzu K
World J Gastroenterol; 2014 Oct; 20(38):13741-55. PubMed ID: 25320512
[TBL] [Abstract][Full Text] [Related]
79. HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Hyman DM; Piha-Paul SA; Won H; Rodon J; Saura C; Shapiro GI; Juric D; Quinn DI; Moreno V; Doger B; Mayer IA; Boni V; Calvo E; Loi S; Lockhart AC; Erinjeri JP; Scaltriti M; Ulaner GA; Patel J; Tang J; Beer H; Selcuklu SD; Hanrahan AJ; Bouvier N; Melcer M; Murali R; Schram AM; Smyth LM; Jhaveri K; Li BT; Drilon A; Harding JJ; Iyer G; Taylor BS; Berger MF; Cutler RE; Xu F; Butturini A; Eli LD; Mann G; Farrell C; Lalani AS; Bryce RP; Arteaga CL; Meric-Bernstam F; Baselga J; Solit DB
Nature; 2018 Feb; 554(7691):189-194. PubMed ID: 29420467
[TBL] [Abstract][Full Text] [Related]
80. HER family inhibitors in pancreatic cancer: current status and future directions.
Berz D; Miner T; McCormack E; Safran H
Expert Opin Ther Targets; 2007 Mar; 11(3):337-47. PubMed ID: 17298292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
